Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis
Paul L de Zwart,Bart R J van Dijken,Gea A Holtman,Gilles N Stormezand,Rudi A J O Dierckx,Peter Jan van Laar,Anouk van der Hoorn,Paul L. de Zwart,Bart R.J. van Dijken,Gea A. Holtman,Gilles N. Stormezand,Rudi A.J.O. Dierckx
DOI: https://doi.org/10.2967/jnumed.119.233809
2019-09-20
Journal of Nuclear Medicine
Abstract:Posttreatment high-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is limited as it cannot adequately distinguish between true tumor progression and treatment-related changes. According to recent Response Assessment in Neuro-Oncology recommendations, PET overcomes this limitation. However, it is currently unknown which tracer yields the best results. Therefore, a systematic review and metaanalysis were performed to compare the diagnostic accuracy of the different PET tracers in differentiating tumor progression from treatment-related changes in high-grade glioma patients. <b>Methods:</b> PubMed, Web of Science, and Embase were searched systematically. Study selection, data extraction, and quality assessment were performed independently by 2 authors. Metaanalysis was performed using a bivariate random-effects model when at least 5 studies were included. <b>Results:</b> The systematic review included 39 studies (11 tracers). <sup>18</sup>F-FDG (12 studies, 171 lesions) showed a pooled sensitivity and specificity of 84% (95% confidence interval, 72%–92%) and 84% (95% confidence interval, 69%–93%), respectively. <i>O</i>-(2-<sup>18</sup>F-fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) (7 studies, 172 lesions) demonstrated a sensitivity of 90% (95% confidence interval, 81%–95%) and specificity of 85% (95% confidence interval, 71%–93%). For <i>S</i>-<sup>11</sup>C-methyl)-l-methionine (<sup>11</sup>C-MET) (8 studies, 151 lesions), sensitivity was 93% (95% confidence interval, 80%–98%) and specificity was 82% (95% confidence interval, 68%–91%). The numbers of included studies for the other tracers were too low to combine, but sensitivity and specificity ranged between 93%–100% and 0%–100%, respectively, for <sup>18</sup>F-FLT; 85%–100% and 72%–100%, respectively, for 3,4-dihydroxy-6-<sup>18</sup>F-fluoro-l-phenylalanine (<sup>18</sup>F-FDOPA); and 100% and 70%–88%, respectively, for <sup>11</sup>C-choline. <b>Conclusion:</b> <sup>18</sup>F-FET and <sup>11</sup>C-MET, both amino-acid tracers, showed a comparably higher sensitivity than <sup>18</sup>F-FDG in the differentiation between tumor progression and treatment-related changes in high-grade glioma patients. The evidence for other tracers is limited; thus, <sup>18</sup>F-FET and <sup>11</sup>C-MET are preferred when available. Our results support the incorporation of amino-acid PET tracers for the treatment evaluation of high-grade gliomas.
radiology, nuclear medicine & medical imaging